State of Wisconsin Investment Board cut its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 31.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 228,532 shares of the medical research company’s stock after selling 106,302 shares during the period. State of Wisconsin Investment Board owned 0.11% of Edwards Lifesciences Corporation worth $24,981,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of EW. Atria Investments LLC increased its stake in shares of Edwards Lifesciences Corporation by 3.0% in the second quarter. Atria Investments LLC now owns 3,856 shares of the medical research company’s stock worth $456,000 after purchasing an additional 113 shares during the period. NEXT Financial Group Inc increased its stake in Edwards Lifesciences Corporation by 62.4% during the second quarter. NEXT Financial Group Inc now owns 1,697 shares of the medical research company’s stock valued at $201,000 after acquiring an additional 652 shares during the period. Mn Services Vermogensbeheer B.V. increased its stake in Edwards Lifesciences Corporation by 513.9% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 35,002 shares of the medical research company’s stock valued at $4,139,000 after acquiring an additional 29,300 shares during the period. Ledyard National Bank increased its stake in Edwards Lifesciences Corporation by 2.4% during the second quarter. Ledyard National Bank now owns 50,556 shares of the medical research company’s stock valued at $5,978,000 after acquiring an additional 1,170 shares during the period. Finally, Beese Fulmer Investment Management Inc. increased its stake in Edwards Lifesciences Corporation by 4.0% during the second quarter. Beese Fulmer Investment Management Inc. now owns 29,539 shares of the medical research company’s stock valued at $3,493,000 after acquiring an additional 1,127 shares during the period. Institutional investors and hedge funds own 82.32% of the company’s stock.

In related news, VP Donald E. Bobo, Jr. sold 5,300 shares of the company’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $112.15, for a total value of $594,395.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Larry L. Wood sold 18,960 shares of the company’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $111.81, for a total transaction of $2,119,917.60. The disclosure for this sale can be found here. Insiders have sold a total of 138,580 shares of company stock valued at $15,039,844 in the last quarter. Corporate insiders own 2.13% of the company’s stock.

Several brokerages recently issued reports on EW. Deutsche Bank AG lowered their price target on Edwards Lifesciences Corporation from $122.00 to $115.00 and set a “hold” rating on the stock in a research note on Thursday, October 26th. Morgan Stanley lowered their price target on Edwards Lifesciences Corporation from $133.00 to $120.00 and set an “overweight” rating on the stock in a research note on Thursday, October 26th. Barclays PLC lowered their price target on Edwards Lifesciences Corporation from $120.00 to $118.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 25th. SunTrust Banks, Inc. set a $124.00 price target on Edwards Lifesciences Corporation and gave the company a “buy” rating in a research note on Wednesday, October 25th. Finally, Canaccord Genuity restated a “buy” rating and set a $135.00 price target (down from $155.00) on shares of Edwards Lifesciences Corporation in a research note on Wednesday, October 25th. Seven research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $125.17.

Shares of Edwards Lifesciences Corporation (EW) opened at $103.85 on Friday. The company has a market cap of $22,173.53, a price-to-earnings ratio of 29.02, a price-to-earnings-growth ratio of 1.88 and a beta of 0.46. Edwards Lifesciences Corporation has a 1 year low of $81.12 and a 1 year high of $121.45. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33.

Edwards Lifesciences Corporation (NYSE:EW) last issued its earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the consensus estimate of $0.86 by ($0.02). The business had revenue of $821.50 million for the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. The business’s revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.68 EPS. equities research analysts forecast that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Edwards Lifesciences Corporation (EW) Stake Lowered by State of Wisconsin Investment Board” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.watchlistnews.com/edwards-lifesciences-corporation-ew-stake-lowered-by-state-of-wisconsin-investment-board/1695580.html.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.